Document is current
Any future updates will be listed below
-
Authors
Xia, Lingfeng
Yang, Qingyan
Jiang, Lingjun
Zheng, Yu
Chen, Leilei
Lin, Song
Reinhardt, Jan D.
Lu, Xiao
- License Information
-
More Information
Article History
Received: 8 March 2024
Accepted: 27 January 2025
First Online: 21 February 2025
Declarations
:
: The Institutional Review Board of the First Affiliated Hospital of Nanjing Medical University has sanctioned the trial protocol (Reference No. 2023-SR-161). Any substantive modifications pertaining to the study protocol, be it eligibility criteria, intervention methodologies, outcome measures, or analytical approaches, will be executed under the vigilant oversight and endorsement of the respective review board. All endeavors undertaken in this trial with human participants shall align scrupulously with the rigorous ethical tenets set forth by both the institutional/national research committees and the 1964 Helsinki Declaration, inclusive of subsequent amendments or analogous ethical benchmarks. Prior to their enrolment and allocation, explicit written consents shall be procured from all participating individuals.
: Not applicable.
: The authors declare that they have no competing interests.
